Cancer Glycogene Discovery Service

Altered Glycosylation in Cancer

Altered glycosylation is a recognized hallmark of cancer, mediating tumor cell interactions, affecting cell-matrix interactions, leading to harmful metabolism and cell signaling, etc. The cancer genome reveals changes in the expression of some glycosylation-specific genes in cancer. For example, many isoforms of the GALNT and GalNAcT families are absent from healthy tissues but are highly expressed in cancer cells, making them reliable biomarkers for cancer diagnosis, monitoring, and treatment. Considerable work remains devoted to large-scale analysis of glycosylation genes in human tumors to help improve diagnostic methods, treatment standards, and ultimately cancer prevention.

Fig.1 Role of glycans in cancer development and progression. (Pinho & Reis, 2015)

Cancer Glycogene Discovery Service at CD BioGlyco

With the advanced Glycogenomics Platform, CD BioGlyco provides clients with comprehensive Expression Profiling services in cancer. We apply various methods to help clients study glycogenes in cancer at an advanced level. Our services include but are not limited to:

Fig.2 Technologies for glycogene expression profiling in cancer. (CD BioGlyco)

Glycogene Discovery Service in Cervical Cancer

Abnormal expression of glycosyltransferase affects cervical cancer cell attachment and cytoskeletal reorganization. Increased expression of ST6Gal 1, ST3Gal 3, and MUC1 has been found in cervical cancer cells.

Glycogene Discovery Service in Leukemia

GSK-3α is a therapeutic target for acute myeloid leukemia (AML). GSK-3β controls leukemia cell resistance to chemotherapy. We provide clients with glycogene expression analysis services in leukemia cells to discover more potential genes.

Glycogene Discovery Service in Bladder Cancer

The glycoprotein is overexpressed in more aggressive bladder tumors and is widely used as a biomarker for bladder cancer stem cells. The uses and potential of ST3GAL6, C1GALT1, etc. in medicine have been discovered.

Glycogene Discovery Service in Colorectal Adenocarcinoma

Many glycolysis-related molecules are involved in the regulation of glucose metabolism in colorectal cancer cells. We analyze glycolysis-related genes through bioinformatics and establish a glycolysis-based risk model to discover new biomarkers in colorectal cancer.

Glycogene Discovery Service in Liver Cancer

Our NGS-based transcriptome and immunohistochemistry methods measure the expression levels of glycogenes in liver cancer and reveal differences in glycoprotein expression between normal cells and cancer cells.

Glycogene Discovery Service in Lymphoma

GSK3, GAPDH, GLUTs, etc. are involved in the occurrence and development of lymphoma cells. CD BioGlyco provides glycogene expression profiling services to discover and identify more glycogenes in lymphoma cells.

Glycogene Discovery Service in Breast Cancer

It is urgent to find potential biomarkers and functional targets that can be applied to personalized precision treatment and reduce breast cancer mortality. Many glycogenes related to breast cancer have been discovered so far, such as CA153, CA125, CA549, MGAT5, etc.

Glycogene Discovery Service in Prostate Cancer

Increased sialylation and fucosylation in prostate cancer cells could alter protein function and play key roles in many biological processes. The process is regulated by the expression of glycogenes. We provide comprehensive expression profiling services for prostate cancer cells.

Glycogene Discovery Service in Pancreatic Cancer

We provide clients with glycogene expression analysis services in pancreatic cancer through western blotting, immunohistochemistry, RNA interference, and other methods to explore and characterize new glycosylation genes.

Glycogene Discovery Service in Lung Cancer

We used NGS to measure the expression levels of genes in cancer cells to reveal differences in glycoprotein expression between normal cells and lung cancer cells.

Glycogene Discovery Service in Thyroid Cancer

We perform gene expression profiling on thyroid patient tissues to identify abnormally expressed glycogenes. These genes may represent new molecular markers that may contribute to their diagnostic, prognostic, and possible therapeutic implications.

Glycogene Discovery Service in Ovarian Cancer

ST6GAL1 and MUC16 are abnormally expressed in ovarian cancer tissues. We provide glycogene expression analysis services for our clients to comprehensively detect genes in ovarian cancer and develop new biomarkers.

Applications

We perform a comprehensive analysis of glycogene expression in cancer to identify their expression signatures and potentially altered glycosylation pathways.
We analyze glycogene signatures or the expression levels of the proteins they encode to explore whether they can be used as putative biomarkers.
Identification of new specific glycogenes for use in cancer diagnosis and treatment.

Advantages of Us

Comprehensive expression analysis of genes in cancer cells through high-throughput technologies such as microarrays and NGS.
To further identify glycogene expression signatures in cancer cells, we perform hierarchical clustering analysis on the samples after removing low-expressed glycogenes.
An experienced team of scientists and a high-quality technical platform guarantee your services.

With an advantageous glycogenomics platform, CD BioGlyco uses a variety of expression analysis technologies to help clients analyze glycosylation genes in cancer to explore new biomarkers. If you have related project needs, please feel free to contact us.

Reference

Pinho, S.S.; Reis, C.A. Glycosylation in cancer: mechanisms and clinical implications. Nature Reviews Cancer. 2015, 15(9): 540-555.

This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Important Links

Contact Us